LCIのチャート
LCIの企業情報
| symbol | LCI |
|---|---|
| 会社名 | Lannett Co. Inc. （LANNETT COMPANY） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | ラネット・カンパニー（Lannett Company Inc.）はジェネリック医薬品（後発医薬品）を開発、製造、販売、販売する。同社は、子会社Silarx Pharmaceuticals、Inc.によって製造された小売店頭商品の小規模ポートフォリオを除き、処方薬品を製造および/あるいは販売を行う。2016年6月30日現在、同社の製品には、アセタゾラミド錠、ブタルビタール、アセトアミノフェンおよびカフェイン錠、アスピリンおよびカフェインカプセル、C-局所溶液、ジゴキシン錠、Glycolax Rx、一硝酸イソソルビドCR、レボチロキシンNa錠、メチルフェニデートHCL CD、メチルフェニデートER、ニフェジピンCR、オメプラゾールDR、オキシブチニンER、ピロカルピンHCl錠、パントプラゾールDR、トリアムテレンw/ヒドロクロロチアジドカプセルおよびウルソジオールカプセルが含まれる。同社が開発中の製品は経口固体製品（錠剤/カプセル）、経口溶液、鼻用医薬、局所適用および注射用製品などを含む。 ラネットは米国の医薬品メ―カ―。ブランド医薬品のジェネリック版の開発、製造、販売。固体経口、徐放性、局所、経鼻および経口の仕上げ溶剤を提供。 主要製品は、甲状腺疾患用のレボチロキシンナトリウム、うっ血性心不全のためのジゴキシン、片頭痛のためにブタルビタ―ルを含む製品、麻酔薬「コカイン・トピカル」、鎮痛剤としての硫酸モルヒネ経口溶剤など。 Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. |
| 本社所在地 | 9000 State Road Philadelphia PA 19136 USA |
| 代表者氏名 | Patrick G. LePore |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 215-333-9000 |
| 設立年月日 | 15311 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 1251人 |
| url | www.lannett.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 209.88800 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 318.22260 |
| 売上高 | （百万ドル） 694.06900 |
| 企業価値(EV) | （百万ドル） 967.90060 |
| 当期純利益 | （百万ドル） -280.15500 |
| 決算概要 | BRIEF: For the six months ended 31 December 2018 Lannett Company Inc. revenues increased 3% to $348.8M. Net loss before extraordinary items totaled $275.2M vs. income of $43.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Asset impairment charges increase from $0K to $369.5M (expense) Other decrease from $3.1M (income) to $1M (expense). |
LCIのテクニカル分析
LCIのニュース
Lannett Down 27% After NYSE Suspension; Creditor Talks Continue 2023/04/20 16:50:00 MarketWatch
By Josh Beckerman Lannett Co. shares fell 27% to 50 cents as they began trading over-the-counter after their suspension from the New York Stock Exchange. The…
NYSE to delist Lannett Company, will trade in OTC market 2023/04/20 11:09:23 Seeking Alpha
Lannett Company (LCI) received a notice from NYSE dated April 19, 2023, notifying that NYSE will commence proceedings to delist the stock
Lannett CFO John Kozlowski to step down 2023/04/14 22:19:03 Seeking Alpha
Lannett (LCI) on Friday said its CFO John Kozlowski would depart on May 16. Read more here.
Lysol® Pro Solutions collaborates with LCI to create employment opportunities for people who are blind or visually impaired 2023/04/13 14:00:00 Kwhen Finance
7 Stocks to Sell as Borrowing Costs Rise 2023/02/28 19:46:33 InvestorPlace
With major economic weakness possibly lurking around the corner, investors should consider targeting stocks to sell. Specifically, market participants should note securities that feature rising short borrow fees. As the name suggests, brokerage firms charge fees to clients who borrow shares for shorting purposes. Further, the more difficult the underlying security is to borrow, the higher the fee. On paper, rising borrowing costs indicate greater demand among short sellers, which is naturally bearish for impacted enterprises. True, the risk of the contrarian wave – the short squeeze – may rise as borrowing costs go northward. However, some enterprises feature flawed financials or fundamental headwinds. Therefore, you may want to avoid the below stocks to sell. RKT Rocket Companies $7.98 LCI Lannett Company $2.09 ECOR electroCore $3.47 CVNA Carvana $9.76 GNUS Genius Brands $3.22 MARA Marathon Digital $7.47 GETY Getty Images $6.48 Rocket Companies (RKT) Source: Shutterstock While Rocket Companies (NYSE: RKT ) enjoyed a decent run this year, circumstances may sour soon.
PE Firm Stellex Capital Management Acquires Fintellix, G2 and LCI 2023/01/05 18:27:58 ChannelE2E
Private equity firm Stellex makes three acquisitions to form what the buyer refers to as ''a tech-enabled risk and compliance platform.'' The post PE Firm Stellex Capital Management Acquires Fintellix, G2 and LCI appeared first on ChannelE2E: Technology News for MSPs & Channel Partners .
Stellex Buys G2, LCI and Fintellix 2023/01/03 16:37:13 The Middle Market
The platform is focused on providing risk, fraud mitigation and regulatory compliance services to theirbclients within the financial and digital commerce sectors.
TransUnion finanlizes sale of G2, LCI and Fintellix for $176M (NYSE:TRU) 2023/01/03 12:05:52 Seeking Alpha
TransUnion (TRU) has finalized the sale of G2 Web Services, Lundquist Consulting and Fintellix India Private Limited to an affiliate of investment firm Stellex Capital…
TransUnion Completes Sale of G2, LCI and Fintellix to Stellex Capital Management for $176 million 2023/01/03 11:45:00 GlobeNewswire
CHICAGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- TransUnion (NYSE: TRU) completed the previously announced sale of G2 Web Services, Inc. (“G2”), Lundquist Consulting, Inc. (“LCI”) and Fintellix India Private Limited (“Fintellix”), to an affiliate of Stellex Capital Management LLC (“Stellex”), a global, multi sector investment firm for $176 million of consideration, subject to customary purchase price adjustments.
Stellex Capital Management LLC Acquires G2, LCI, and Fintellix 2023/01/03 11:45:00 Business Wire
NEW YORK--(BUSINESS WIRE)-- #acquisition--An affiliate of Stellex Capital Management LLC (“Stellex”) has acquired G2 Web Services, Inc. (“G2”), Lundquist Consulting, Inc. (“LCI”) and Fintellix India Private Limited (“Fintellix”, together with G2 and LCI, the “Platform”) from TransUnion (NYSE: TRU). The Platform is comprised of leading and tenured businesses, focusing on deploying sophisticated data-driven solutions to provide mission-critical risk, fraud mitigation, and regulatory compliance services to their
Investing in Lannett Company Inc. (LCI) might be a great opportunity, but the stock is a bit overvalued 2022/12/21 13:54:00 US Post News
As of Tuesday, Lannett Company Inc.’s (NYSE:LCI) stock closed at $0.80, up from $0.71 the previous day. While Lannett Company Inc. has overperformed by 13.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LCI fell by -52.94%, with highs and lows ranging from $1.91 to $0.38, […]
Lannett Company Inc. (LCI) produces promising results 2022/11/24 12:48:00 US Post News
In Wednesday’s session, Lannett Company Inc. (NYSE:LCI) marked $0.71 per share, up from $0.68 in the previous session. While Lannett Company Inc. has overperformed by 3.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LCI fell by -56.70%, with highs and lows ranging from $2.16 to […]
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday 2022/11/22 08:49:19 Benzinga
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO ) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC ) jumped 44.5% to close at $1.20. NeuroOne, last month, received FDA 510(k) clearance to market its Evo sEEG System for less than 30 day use. OncoSec Medical Incorporated (NASDAQ: ONCS ) gained 42.2% to close at $4.85. OncoSec Medical recently announced early clinical data from an investigator-sponsored trial of TAVO in combination with Bristol-Myers Squibb’s intravenous Opdivo (nivolumab). Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO ) surged 40.3% to close at $2.47. NWTN Inc. (NASDAQ: NWTN ) jumped 38.8% to close at $7.05. SeaStar Medical Holding Corporation (NASDAQ: ICU ) shares jumped 33.6% to close at $5.25. Sotera Health Company (NASDAQ: SHC ) gained 32.9% to close at $8.00. Barclays, last week, downgraded Sotera Health from Equal-Weight to Underweight and lowered the price target from $7 to $6.
LCI stock gains on patent deal for biosimilar insulin device (NYSE:LCI) 2022/11/07 20:06:31 Seeking Alpha
The shares of generic drugmaker Lannett Company (LCI) added ~9% on Monday after announcing a licensing deal for patents related to a pen injector device for its investigational…
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM 2022/11/07 11:52:00 Benzinga
TREVOSE, Pa. , Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI ) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs, that will provide a patent sublicense to the company and its strategic alliance partner within the HEC Group of companies (HEC). Under the agreement, Lannett and HEC will, in exchange for its financial contribution, receive a … Full story available on Benzinga.com